Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy

Fernandes, Renata Salgado; Silva, Juliana O.; Monteiro, Liziane O.F.; Leite, Elaine Amaral; Cassali, Geovanni Dantas; Rubello, Domenico; Cardoso, Valbert Nascimento; Ferreira, Lucas Antônio Miranda; Oliveira, Mônica Cristina; Barros, André Luís Branco de

doi:10.1016/j.biopha.2016.09.032

Cited by 40 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stability assays were carried out in order to allow in vivo experiments (blood clearance, biodistribution and scintigraphic images). In addition, tumor uptake was evaluated in a 4T1 tumor model, which is widely used in pre-clinical research for testing new imaging probes and to evaluate the pharmacokinetics and antitumor activity of new potential chemotherapeutics [12,13,27]. This mammary carcinoma cell line, derivate from a spontaneously tumor in BALB/cfC3H mice, was originally isolated by Fred Miller and coworkers at the Karmanos Cancer Institute [28,29].…”

Section: Discussionmentioning

confidence: 99%

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Monteiro

Fernandes

Castro

et al. 2017

Biomedicine & Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

The high incidence and mortality of breast cancer supports efforts to develop innovative imaging probes to effectively diagnose, evaluate the extent of the tumor, and predict the efficacy of tumor treatments while concurrently and selectively delivering anticancer agents to the cancer tissue. In the present study we described the preparation of technetium–99 m (99mTc)-labeled paclitaxel (PTX) and evaluated its feasibility as a radiotracer for breast tumors (4T1) in BALB/c mice. Thin Layer Chromatography (TLC) was used to determine the radiochemical purity and in vitro stability of 99mTc-PTX. PTX micelles showed a unimodal distribution with mean diameter of 13.46 ± 0.06 nm. High radiochemical purity (95.8 ± 0.3%) and in vitro stability (over than 95%), up to 24 h, were observed. Blood circulation time of 99mTc-PTX was determined in healthy BALB/c mice. 99mTc-PTX decays in a one-phase manner with a half-life of 464.3 minutes. Scintigraphic images and biodistribution were evaluated at 4, 8 and 24 h after administration of 99mTc-PTX in 4T1 tumor-bearing mice. The data showed a significant uptake in the liver, spleen and kidneys, due to the importance of these routes for excretion. Moreover, high tumor uptake was achieved, indicated by high tumor-to-muscle ratios. These findings indicate the usefulness of 99mTc-PTX as a radiotracer to identify 4T1 tumor in animal models. In addition, 99mTc-PTX might be used to follow-up treatment protocols in research, being able to provide information about tumor progression after therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Monteiro

Fernandes

Castro

et al. 2017

Biomedicine & Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…LA-DOX was synthesized as reported by Fernandes et al (2016) with some modifications. Briefly, an aqueous solution of Doxorubicin hydrochloride (5 mg/mL) was neutralized with a solution of sodium bicarbonate solution (50 mg/mL).…”

Section: Linoleic Acid-doxorubicinmentioning

confidence: 99%

Optimizing the Pharmacological Properties of Discoidal Polymeric Nanoconstructs Against Triple-Negative Breast Cancer Cells

Ferreira

Rizzuti

Palange

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Fine-tuning loading and release of therapeutic and imaging agents associated with polymeric matrices is a fundamental step in the preclinical development of novel nanomedicines. Here, 1,000 × 400 nm Discoidal Polymeric Nanoconstructs (DPNs) were realized via a top-down, template-based fabrication approach, mixing together poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol)-diacrylate (PEG-DA) chains in a single polymer paste. Two different loading strategies were tested, namely the "direct loading" and the "absorption loading." In the first case, the agent was directly mixed with the polymeric paste to realize DPNs whereas, in the second case, DPNs were first lyophilized and then rehydrated upon exposure to a concentrated aqueous solution of the agent. Under these two loading conditions, the encapsulation efficiencies and release profiles of different agents were systematically assessed. Specifically, six agents were realized by conjugating lipid chains (DSPE) or polymeric chains (PEG) to the near-infrared imaging molecule Cy5 (DSPE-Cy5 A and DSPE-Cy5 B); the chemotherapeutic molecules methotrexate (DSPE-MTX and PEG-MTX) and doxorubicin (LA-DOX and DSPE-DOX). Moderately hydrophobic compounds with low molecular weights (MW) returned encapsulation efficiencies as high as 80% for the absorption loading. In general, direct loading was associated with encapsulation efficiencies lower than 1%. The agent hydrophobicity and MW were shown to be critical also in tailoring the release profiles from DPNs. On triple-negative breast cancer cells (MDA-MB-231), absorption loaded DOX-DPNs showed cytotoxic activities comparable to free DOX but slightly delayed in time. Preliminary in vivo studies demonstrated the high stability of Cy5-DPNs. Collectively, these results demonstrate that the pharmacological properties of DPNs can be finely optimized by changing the loading strategies (direct vs. absorption) and compound attributes (hydrophobicity and molecular weight).

show abstract

“…Studies utilizing liposomal-based NPs for PCa and BC theranostic techniques are few [238,239,240,241,242,243,244,245,246,247], although applications for therapy or imaging alone are significantly more frequently published [248,249,250,251,252,253,254,255,256,257,258,259,260,261]. For example, Yeh et al recently published results from experiments investigating peptide-conjugated liposomal NPs in a theranostic approach for PCa.…”

Section: Nanoparticles For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy

Cited by 40 publications

References 28 publications

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Optimizing the Pharmacological Properties of Discoidal Polymeric Nanoconstructs Against Triple-Negative Breast Cancer Cells

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About